DIRS.INFO The most relevant business & tech news

☆ Why we see a way forward for Nvidia in China — plus our take on 2 other stocks in the news
▼ + stars: | 2023-12-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Meanwhile, Jim Cramer's interview with an influential member of President Joe Biden's cabinet proved encouraging for Club holding Nvidia . It's been a two-session roller-coaster ride that illustrates the importance of staying disciplined and not chasing stocks while they're surging for non-fundamental reasons. Traders were trying to front-run the official announcement, pushing Linde stock up 4.53% Tuesday, to an all-time high of $426.72 per share. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Nvidia CEO Jen-Hsun Huang at the Consumer Elctronics Show (CES) in Las Vegas, USA, 04 January 2017.

Persons: Linde, Jim Cramer's, Joe Biden's, It's, Pfizer's, drugmaker Seagen, there's, Gina Raimondo, Jim, Biden, Raimondo, " Raimondo, Cigna, Humana's, —, Humana, Aetna's, Jim Cramer, Jen, Hsun Huang, Huang, Andrej Sokolow Organizations: Club, Nvidia, LIN, Linde, Nasdaq, Traders, . Commerce, U.S, Bank of America, Wall Street Journal, Humana, CNBC, Consumer, Audi, Getty Locations: China, U.S, Wall, Las Vegas, USA

☆ S&P 500 rises to 20-month high with a soft landing in sight. Can investors finally relax?
▼ + stars: | 2023-12-09 | by ( Michael Santoli | ) www.cnbc.com time to read: +9 min

The S & P 500 , which had consolidated with a low-volatility sideways slide for three weeks, nudged to a new 20-month high just above 4600, almost precisely a 20% year-to-date gain. Just because the S & P 500 is at 4600 and Federal-funds futures markets project high odds of several rate cuts next year, it doesn't mean the former is reliant on the latter. Yet — just relax — in seven of the past 12 years, the S & P 500 went on to surpass this year-ahead analyst composite target. It's pretty popular to cast doubt on the achievability of the consensus 11.8% forecast S & P 500 earnings growth for 2024. A broadening beyond 2023's growth leadership is necessary for further S & P 500 gains.

Persons: YTD, Jerome Powell, Powell, John Butters, Scott Chronert Organizations: Federal, Fed, Bank of America, Wall, Merck, Pfizer, Citi, Treasury

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

Dec 5 (Reuters) - Eli Lilly (LLY.N) on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's (NOVOb.CO) rival obesity drug Wegovy to hit around $7.5 billion. An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. When the U.S. Food and Drug Administration approved Zepbound in November, Lilly said it would launch after the U.S. Thanksgiving holiday. Lilly's obesity drug has the same active ingredient, tirzepatide, as its previously approved diabetes drug Mounjaro, which has been used off-label for weight loss since its 2022 launch.

Persons: Eli Lilly, Wegovy, danuglipron, Zepbound, Lilly, Mike Segar, Eli Lilly's, Patrick Wingrove, Manas Mishra, Khushi, Arun Koyyur, Alexander Smith, Bill Berkrot Organizations: Wall Street, Novo, Pfizer, Company, REUTERS, CVS, U.S . Food, Drug Administration, U.S, Thomson Locations: U.S, Branchburg , New Jersey, Indianapolis, New York, Bengaluru

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's

☆ Blackstone explores sale of Anthos Therapeutics -sources
▼ + stars: | 2023-12-04 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

Signage is seen outside the Blackstone Group headquarters in New York City, U.S., January 18, 2023. Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said. The company's anticoagulants have made significant progress in late-stage clinical trials, the sources added. Blackstone is working with investment bankers to explore a sale of Anthos, the sources said, cautioning that no deal is certain and requesting anonymity because the matter is confidential. Anthos has licensed from Novartis an antibody used in the development of its blood thinners and granted it a minority stake.

Persons: Blackstone, Anthos, Bayer, Eliquis, David Carnevali, Leslie Adler Organizations: Blackstone Group, REUTERS, Blackstone Inc, Anthos Therapeutics, Novartis AG, Novartis, Myers Squibb, Alnylam Pharmaceuticals, Thomson Locations: New York City, U.S, Cambridge , Massachusetts, Anthos, Bristol, German, New York

☆ Cramer on Monday's market action: Some investors are headed for a 'nasty hangover'
▼ + stars: | 2023-12-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

"I saw a hammered market, a market where the buyers have gotten drunk as a proverbial skunk, buying the worst of the worst," he said. But as the mini banking crisis receded, the market broadened out and investors "collectively got a nice buzz going," Cramer said. They looked towards other sectors with strong potential, buying shares of artificial intelligence companies, cybersecurity outfits and weight loss drug manufacturers, he said. But some overindulged, he said, and now the "hammered investors have taken over." "For those who're slamming them down now and buying stocks under the influence?

Persons: CNBC's Jim Cramer, Cramer, Estee Lauder Organizations: Wall, Moderna, Pfizer Locations: China

☆ Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
▼ + stars: | 2023-12-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That includes Novo Nordisk 's Wegovy and diabetes treatment Ozempic as well as Eli Lilly 's diabetes drug Mounjaro. They have all skyrocketed in popularity — and slipped into shortages — over the last year for safely and successfully causing significant weight loss. But before the current weight loss industry gold rush, the path to treating obesity was strewn with failures dating back decades. In its full-year 2019 earnings, Eisai reported that Lorcaserin had sales of $28.1 million in the U.S. for the year. Sanofi's rimonabantAn obesity drug called rimonabant from Sanofi and Aventis was withdrawn from all markets in 2008 due to the risk of serious psychiatric problems, including suicide.

Persons: Eli Lilly, drugmakers, lorcaserin, Eisai, Lorcaserin Organizations: Getty, Pfizer, Novo Nordisk, U.S, Drug Administration, FDA, Aventis, Abbott Laboratories Locations: U.S, Sanofi

☆ We're updating price targets for 6 stocks and changing our rating for Palo Alto
▼ + stars: | 2023-12-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

The Club on Friday is changing the rating and price target on one of our favorite stocks, and updating the price targets on 5 other names in the portfolio to reflect recent quarterly earnings reports, new developments at the companies and broader economic forces. We're increasing our price target on shares of Palo Alto (PANW) to $300 from $280. We're raising our price target on shares of Salesforce (CRM) to $275 from $240. We're lowering our price target for Ford (F) stock to $13 from $16. We're lifting our price target on shares of Eli Lilly (LLY) to $630 from $600.

Persons: PANW, Ford, Linde's, Linde, Eli Lilly, it's, It's, Jim Cramer's, Jim Cramer, Jim Organizations: Palo, Palo Alto Networks, Costco, Ford, UAW, Management, Motors, GM, Linde, LIN, P Healthcare, donanemab, Novo Nordisk, Pfizer, CNBC Locations: Alzheimer's, Lilly, Santa Clara , California

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 27, 2023. Market participants now await policy comments from Powell at two separate discussions scheduled for 11 a.m. After recent conflicting remarks from other policymakers, investors are concerned that Powell could push back against the rate cut narrative. Other officials, including Fed Governors Lisa Cook and Chicago Fed President Austan Goolsbee are also scheduled to speak during the day. Reporting by Shristi Achar A and Amruta Khandekar in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Powell, Jerome Powell's, Dow Jones, underscoring, Sophie Lund, Yates, Hargreaves Lansdown, Lisa Cook, Austan Goolsbee, Alibaba, Morgan Stanley, danuglipron, Paula Oyibo, Shristi Achar, Shinjini Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Federal, Chicago Fed, P Global, ISM, Dow e, Pfizer, Marvell Technology, Automation, Thomson Locations: New York City, U.S, Bengaluru

☆ Pfizer drops plan to study twice-daily obesity pill in late-stage studies
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +2 min

A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile". In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes. Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial. However, no new safety signals were observed in the study, Pfizer said.

Persons: Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini Organizations: Pfizer, REUTERS, Zepbound, Thomson Locations: Manhattan, New York City , New York, U.S, Bengaluru, New York

☆ Competition will make obesity drugs successful
▼ + stars: | 2023-12-01 | by ( Robert Cyran | ) www.reuters.com time to read: +3 min

In an interview with the Financial Times, he proposed spreading reimbursements over time if the medication proves to be successful. There’s some practical grounding in that solution, but the path of other similar drugs suggests that a competitive market is a better way to make it successful. Snag is, the drugs cost several thousand dollars per patient annually, even after discounts. Medicare, which covers 66 million seniors, can’t pay for weight loss drugs under current law. While it makes more sense for insurers or governments to pay over time if the drugs benefits last, schemes like the one that Jørgensen suggests can only do so much.

Persons: Lars Fruergaard Jørgensen, Jørgensen, “, Lauren Silva Laughlin, Sharon Lam Organizations: Reuters, Novo Nordisk, Financial Times, Centers for Disease Control, Prevention, North Carolina, The New England, of Medicine, Employers, Thomson Locations: U.S, The, United States, Danish

☆ Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
▼ + stars: | 2023-12-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year. Pfizer's phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. Meanwhile, placebo-adjusted weight loss was 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks, Pfizer said. No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer's other discontinued weight loss pill.

Persons: Albert Bourla, Eli Lilly, danuglipron Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy

Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. But Novo and Pfizer are also trying to develop pill versions that would be easier for patients to take. Pfizer said it saw patient discontinuation rates topping 50% across all doses in a mid-stage study of twice-daily danuglipron. It ranged from nearly 7% to more than 11% in patients taking the pills. By comparison, obese patients without diabetes lost about 18% of their weight compared to a placebo when taking taking Eli Lilly’s Zepbound in late-stage research.

Persons: Eli Lilly, Eli Lilly’s Zepbound, Mikael Dolsten Organizations: Pfizer, Novo Nordisk, Novo, Drug Administration, Pfizer Inc Locations: York

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

☆ Stocks making the biggest moves premarket: Pfizer, Disney, Tesla, Alibaba and more
▼ + stars: | 2023-12-01 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Pfizer — Shares dropped 4.2% after the drugmaker said it would halt development of its twice-daily experimental weight loss pill. Marvell Technology — The semiconductor stock fell more than 5% after Marvell issued lower-than-expected revenue guidance for the fourth quarter. Ulta Beauty — The stock gained nearly 12% after the beauty products retailer reported third-quarter earnings that beat analysts' expectations. Ulta reported earnings of $5.07 per share, higher than the $4.95 per share analysts polled by LSEG were expecting. Dell — Stock in the computer maker fell nearly 6% on the heels of a mixed third-quarter earnings report.

Persons: Pfizer, Andrew Nowinski, Nelson Peltz, Alibaba, Morgan Stanley, Tesla, Coinbase, Ulta, LSEG, Jessica Fye, Lisa Kailai Han, Jesse Pound, Michelle Fox Organizations: Pfizer —, Paramount Global, Wall Street Journal, Apple, Disney —, Trian Fund Management, Marvell Technology, Marvell, Invest, Nasdaq, Dell —, Wall, LSEG, JPMorgan Locations: —, Wells Fargo

☆ Why investors should stick with Eli Lilly
▼ + stars: | 2023-12-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. The treatment — which Jim Cramer has said could become the greatest-selling drug of all time — received approval from the U.S. Food and Drug Administration last month, bolstering Eli Lilly shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Bond, Jerome Powell, Goldman Sachs, STZ, Eli Lilly, —, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Treasury, Federal, Club, Constellation Brands, Pfizer, U.S . Food, Drug Administration Locations: U.S

☆ Stocks making the biggest moves midday: Tesla, Disney, Alibaba, Ulta Beauty and more
▼ + stars: | 2023-12-01 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Ulta Beauty — The beauty stock rallied nearly 11% after posting third-quarter results that surpassed analysts' estimates. Samsara — Samsara shares popped 16% after the cloud company posted better-than-expected quarterly results and shared stronger-than-expected guidance. The chip company posted third-quarter earnings that topped Wall Street's estimates but shared weaker-than-expected guidance for the current quarter. Ambarella — Shares slipped 1% after Ambarella reported third-quarter gross margins of 62.6%, down from 63.5% in the year-ago period. Otherwise, the semiconductor design company posted quarterly results that topped estimates.

Persons: Tesla, Nelson Peltz, Alibaba, Morgan Stanley, Wells, Dell, Altimmune, Ambarella, Jefferies, Yun Li, Michelle Fox, Sarah Min, Alex Harring, Brian Evans, Jesse Pound Organizations: Disney — Disney, Trian Fund Management, Pfizer, Paramount Global, Street Journal, Paramount, Apple, Marvell Technology, Invest, Nasdaq, Dell —, LSEG, JPMorgan, Norfolk Southern, Bank of America, CSG Locations: Texas, China, Wells Fargo, Norfolk, Ohio

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective. Infectious disease experts have said relative risk reduction is a more meaningful way to judge a vaccine's efficacy than absolute risk reduction. Relative risk shows how well a vaccine protects recipients relative to a study's control group. "Pfizer did not tell the truth about their COVID-19 vaccines," Paxton said in a statement. The status of the probe into Moderna and Johnson & Johnson was not immediately clear.

Persons: Dado Ruvic, Ken Paxton, Paxton, BioNTech, Biden, Johnson, Pfizer, Jonathan Stempel, Caroline Humer, Chizu Nomiyama, Daniel Wallis Organizations: Pfizer, REUTERS, Texas, Republican, Moderna, Johnson, Thomson Locations: Lubbock County, New York, Texas, Moderna

☆ Cramer's Lightning Round: 'I'm not a buyer' of NIO
▼ + stars: | 2023-11-30 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Iron Mountain's year-to-date stock performance. Stock Chart Icon Stock chart icon Q2's year-to-date stock performance. Stock Chart Icon Stock chart icon Pfizer's year-to-date stock performance. Stock Chart Icon Stock chart icon NIO's year-to-date stock performance. Stock Chart Icon Stock chart icon Cava's year-to-date stock performance.

Persons: I've, let's Organizations: Uranium Energy, Uranium Energy Corp, Pfizer, American Airlines, NextEra Energy Partners

☆ AbbVie to buy cancer drugmaker ImmunoGen for $10 billion as Humira faces heat
▼ + stars: | 2023-11-30 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brian Snyder/File Photo Acquire Licensing RightsNov 30 (Reuters) - AbbVie (ABBV.N) will buy ImmunoGen (IMGN.O) for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to buy a developer of 'guided missile' cancer therapies as the company's top-seller Humira grapples with fierce competition. ImmunoGen's Elahere belongs to a new class of treatments called antibody-drug conjugates (ADC) that precisely targets cancer cells, potentially reducing toxicity for other cells. The drug, approved for ovarian cancer patients who have received previous therapies, is also being tested in earlier lines of treatment. AbbVie will also get access to Immunogen's follow-on pipeline of ADCs, including early-stage ovarian cancer candidate IMGN-151 and a mid-stage drug pivekimab sunirine for a rare type of blood cancer. Meanwhile, AbbVie's cancer drugs sales declined more than 8% in the third quarter to $1.51 billion, primarily due to increased competition to Imbruvica.

Persons: Brian Snyder, ImmunoGen's Elahere, AbbVie, IMGN, pivekimab, Immuogen stock's, Immunogen's, Elahere, Imbruvica, Manas Mishra, Leroy Leo, Shinjini Ganguli Organizations: REUTERS, Pfizer, Merck, U.S, Thomson Locations: Cambridge , Massachusetts, U.S, Bengaluru

☆ Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which are designed to directly kill cancer cells and spare healthy ones. Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout. The SPDR S&P Biotech ETF , which focuses on small and midsize biotech companies, rose 3% Thursday. Under the terms of the deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday's closing price.

Persons: AbbVie, ImmunoGen, Michael Schmidt Organizations: Biotech, Mersana Therapeutics, ADC Therapeutics, P Biotech ETF, Nasdaq Biotechnology, ImmunoGen, Pfizer, Merck, CNBC PRO Locations: ADCs

☆ Lightning Round: I'm calling the bottom on Pfizer, says Jim Cramer
▼ + stars: | 2023-11-30 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: I'm calling the bottom on Pfizer, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Iron Mountain, Q2 Holdings, AMC, UEC, Pfizer, American Airlines, NIO, Cava and Nextera.

Persons: Jim Cramer Organizations: Pfizer, Q2 Holdings, AMC, UEC, American Airlines Locations: Cava, Nextera

☆ Fact Check: Iceland has not banned COVID vaccines
▼ + stars: | 2023-11-30 | by ( Reuters Fact Check | ) www.reuters.com time to read: +2 min

A headline shared online falsely claims that Iceland has banned COVID-19 vaccines and cites sudden deaths for which there is no evidence, according to the Icelandic national health authority. Iceland has not banned COVID vaccines and “there are no soaring sudden deaths,” Guðrún Aspelund, chief epidemiologist at the Icelandic Directorate of Health, told Reuters in a Nov. 29 email. In 2021, Iceland along with other Scandinavian countries temporarily discontinued giving some COVID vaccines to younger adults. As of Oct. 5, 80.5% of the population (archived) in Iceland has received the primary course, that is two doses of a COVID vaccine. Iceland has not banned COVID vaccines and vaccination is recommended for specific groups of the population.

Persons: ” Guðrún Aspelund, epidemiologist, Aspelund, Moderna's Spikevax, Read Organizations: Icelandic Directorate of Health, Reuters, Twitter, Facebook, Health, Iceland’s, Pfizer, BioNTech's, Thomson Locations: Iceland

Search resuls for: "Pfizer"

25 mentions found